碳酸锂对Graves甲亢患者摄^(131)I率的影响

The Influence of Li_2CO_3 on ^(131)I Uptake Rate of Thyroid in Patients With Graves Hyperthyroidism

为观察碳酸锂对Graves甲亢患者摄^(131)I率的影响,将15例24h摄^(131)I率<55％,拟进行^(131)I治疗的Graves甲亢患者,给碳酸锂口服每日三次,每次250mg,6天后进行甲状腺摄^(131)I率测定。结果表明:患者口服碳酸锂后,甲状腺摄^(131)I率明显升高(P<0.01)。4h摄^(131)I率平均提高88％;6h摄^(131)I率平均提高73％;24h摄^(131)I率平均提高66％。根据服用碳酸锂后24h甲状腺摄^(131)I率,计算其治疗用^(131)I量为服用碳酸锂前的62％,平均减少了38％。因此碳酸锂可以大大提高Graves甲亢患者摄^(131)I率,降低甲亢患者治疗用^(131)I的剂量。

To evaluate the influence of Li2CO3 on radioactive 131I uptake rate(RAIUR) of thyroid in Graves patients, 15 patients with newly diagnosed, untreated Graves' disease, RAIUR<55% at 24 h and nonsevere or absent Graves ophthalmopathy are assigned to be studied. All subjects are checked up the RAIUR, before after Li2CO3 treatment(250 mg/tid ×6 d). The results show that RAIUR are increased after Li2CO3 treatment (P<0. 01). It is important for Graves patients to accept Li2CO3 treatment before 131I therapy in order to decrease the dosage of 131I needed by patients.